Combined Synopsis/SolicitationPosted Aug 26, 2026·Responses due Sep 2, 2026

Market forecast analyses for West Nile virus (WNV) vaccine and anti-WNV monoclonal antibody for prophylaxis

CDC · CDC OFFICE OF ACQUISITION SERVICES

Stage
Open solicitation
NAICS
541715
Value
Not stated
Solicitation
97469
Set-aside
None stated
PSC
AN11
Place
Atlanta, GA, USA
Contact
Iris Gonzalez (qsx8@cdc.gov)
…Open on SAM.gov
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 97469 in this department, oldest first.

Early notice
None posted
Solicitation
  • Aug 26, 2026 · this notice
    Combined Synopsis/Solicitation
Award
Not yet. Too few past cases at this agency to estimate timing (7 found; 10 needed).

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Decide bid or no bid before the response deadline.
  • Look at the past winners for likely competitors and teaming partners.
  • Follow the opportunity to hear about amendments and the award.

What the notice says

Q&A document added. Due Date for all quotes has been updated to September 2, 2026 at 10am est. This is a combined synopsis/solicitation for commercial services prepared in accordance with the format prescribed in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation. Quotations are being requested, and a separate written solicitation will not be issued. The Centers for Disease Control and Prevention (CDC) is issuing Request for Quotation (RFQ) No. 75D301-26-Q-79208 using the procedures of FAR Part 12, Acquisit… (show all)

ion of Commercial Products and Commercial Services, in conjunction with FAR Part 13, Simplified Acquisition Procedures, for the acquisition of Market Forecast Analyses for West Nile Virus (WNV) Vaccine and Anti-WNV Monoclonal Antibody for Prophylaxis. The acquisition will result in the award of a Time-and-Materials (T&M) purchase order. Description of Requirement The Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD), requires contractor support to conduct two comprehensive market forecast analyses: Human West Nile virus (WNV) vaccine Anti-WNV monoclonal antibody (mAb) for seasonal pre-exposure prophylaxis The contractor shall perform market forecasting, epidemiologic analyses, health economic modeling, stakeholder engagement, commercial assessments, financial analyses, and preparation of peer-reviewed publications in accordance with the attached Statement of Work (SOW). Product or Service Code: AN11 � Health R&D Services, Epidemiology NAICS Code: 541715- Research and Development in the Physical Engineering, and Life Sciences Period of Performance: September 30, 2026 � September 29, 2027 (12 months). Delivery Services shall be performed in accordance with the attached Statement of Work. Deliverables shall be submitted in accordance with the deliverable schedule identified in Section 7 of the Statement of Work. Monthly invoicing is required. Submission Requirements Offerors shall submit the following: Completed pricing for all CLINs. A Time-and-Materials quotation for the entire period of performance. Written acknowledgement of the Statement of Work confirming the ability to perform the required services. Active System for Award Management (SAM) registration, including UEI, with no active exclusions. Any required Artificial Intelligence (AI) disclosures and AI Compliance and Risk Management Plan, if applicable.

Who won similar work

111 award notices on SAM.gov in the last 24 months. Matched by: Same agency (CDC), any industry: a loose match.

Loose match: same agency, any industry. Read the titles before treating these as competitors.

Single-winner award sizes (111): middle half $247K to $9.0M, median $992K; range $14K to $4.5B.

WinnerAwardsValueLast
POLOLEI SOLUTIONS, LLC5$3.3MJul 21, 2026
GLAXOSMITHKLINE, LLC3$1.7BMar 27, 2026
RESEARCH TRIANGLE INSTITUTE Durham NC 27709 USA3$9.8MJun 4, 2026
MERCK SHARP & DOHME LLC · $MRK · $66.6B2$4.5BSep 14, 2026
Pfizer New York NY 10001 USA2$1.2BJun 3, 2026
SEQIRUS USA INC2$663.9MDec 31, 2024
Moderna Princeton NJ 08540 USA2$314.2MJun 3, 2026
SANOFI PASTEUR INC.2$233.3MDec 31, 2024
AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA2$155.3MMay 18, 2026
ASTRAZENECA PHARMACEUTICALS LP2$61.0MDec 31, 2024

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

Investor context
  • $MRK reported $66.6B revenue (12 months to Jun 30, 2026). The median single-winner award in these 111 past awards, $992K, is under 0.1% of that. SEC filing

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 1 of these past winners lobbied Centers For Disease Control & Prevention (CDC) since 2024 (5 filings)
  • 0 of their lobbyists list a past Centers For Disease Control & Prevention (CDC) job
  • $99K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 0 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 1 of the past winners are listed companies
  • 0 insider buys and 7 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.